Real World Data Archives

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

Danielle PillsburyJanuary 8, 2025

Video

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…

CertaraDecember 10, 2024

Brochure

Impactful Real World Evidence Solutions

Simona ColucciOctober 9, 2024

Blog

Using Real World Data in Clinical Trial Submissions

We explore challenges & best practice recommendations to help you implement submission standards when using…

CertaraJune 17, 2024

Case Study

Using Real World Evidence to Inform Treatment Guidelines

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

Danielle PillsburyApril 5, 2023

White Paper

Using Real-world Evidence to Advance Market Access for New Therapeutics

Jim GallagherSeptember 29, 2021

On-Demand Webinar

The Scary Future of Rare Disease Management

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

Jim GallagherSeptember 23, 2021

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

Jim GallagherJune 11, 2021

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

Jim GallagherJune 11, 2021

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim GallagherMay 26, 2021

Real World Data

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

Impactful Real World Evidence Solutions

Using Real World Data in Clinical Trial Submissions

Using Real World Evidence to Inform Treatment Guidelines

Using Real-world Evidence to Advance Market Access for New Therapeutics

The Scary Future of Rare Disease Management

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

Stakeholder perspectives: current and potential benefits

Newsletter sign up

Quick links

Solutions

Contact